Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Overall Survival and Its Interplay with Allogeneic Stem Cell Transplant and Age in Newly Diagnosed AML Patients Treated with Ven/Aza

Diana Abbott, Grace Bosma, Christine M. McMahon, Marc Schwartz, Jonathan A. Gutman, Daniel A. Pollyea

Blood (2022) 140 (Supplement 1): 6181–6182.

https://doi.org/10.1182/blood-2022-169026

Published: 2022

Journal Articles

Clinical and Molecular Features of Highly Durable Response to Azacitidine+Venetoclax in Acute Myeloid Leukemia

Alexander Hayden, Grace Bosma, Jonathan A. Gutman, Maria L. Amaya, Diana Abbott, Clayton Smith, Brett M. Stevens, Craig T. Jordan, Daniel A. Pollyea, Christine M. McMahon

Blood (2022) 140 (Supplement 1): 9163–9164.

https://doi.org/10.1182/blood-2022-171064

Published: 2022

Journal Articles

Response to Intensive Induction Chemotherapy after Failure of Frontline Azacitidine+Venetoclax in Acute Myeloid Leukemia

Christine M. McMahon, Kellen Gil, Maria L. Amaya, Jonathan A. Gutman, Alexander Hayden, Marc Schwartz, Grace Bosma, Diana Abbott, Brett M. Stevens, Clayton Smith, Craig T Jordan, Daniel A. Pollyea

Blood (2022) 140 (Supplement 1): 6185–6186.

https://doi.org/10.1182/blood-2022-170168

Published: 2022

Journal Articles

Outcomes Are Similar Following Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Patients Who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy

Amanda C. Winters, Grace Bosma, Diana Abbott, Mohd Minhajuddin, Craig T Jordan, Daniel A. Pollyea, Jonathan A. Gutman

Blood (2021) 138 (Supplement 1): 3957.

https://doi.org/10.1182/blood-2021-154392

Published: 2021